Last quarter (Q ), Caladrius Biosciences's total revenue was $0.00, a decrease of ― from the same quarter last year. In Q, Caladrius Biosciences's net income was $-6.63M. See Caladrius Biosciences’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 21	Dec 20	Dec 19	Dec 18	Dec 17
Total Revenue	-	$ 0.00	$ 0.00	$ 0.00	$ 0.00	$ 0.00
Cost of Revenue	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-
Operating Expense	$ 27.16M	$ 29.05M	$ 19.14M	$ 20.09M	$ 16.99M	$ 27.59M
Operating Income	$ -27.16M	$ -29.05M	$ -19.14M	$ -20.09M	$ -16.99M	$ -27.59M
Net Non Operating Interest Income Expense	-	-	-	$ 0.00	$ -5.00K	$ -378.00K
Other Income Expense	$ 105.00K	$ 76.00K	$ 132.00K	$ 740.00K	$ 824.00K	$ 273.00K
Pretax Income	$ -27.05M	$ -28.97M	$ -19.01M	$ -19.35M	$ -16.17M	$ -27.70M
Tax Provision	$ -2.48M	$ -1.51M	$ -10.87M	$ 0.00	$ 0.00	$ -11.53M
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -24.57M	$ -27.47M	$ -8.15M	$ -19.36M	$ -16.17M	$ 22.98M
Basic EPS	$ -1.96	$ -7.50	$ -0.53	$ -1.88	$ -1.67	$ 2.56
Diluted EPS	$ -1.96	$ -7.50	$ -0.53	$ -1.88	$ -1.67	$ 2.56
Basic Average Shares	$ 184.03M	$ 3.69M	$ 15.44M	$ 10.32M	$ 9.69M	$ 8.97M
Diluted Average Shares	$ 184.03M	$ 3.69M	$ 15.44M	$ 10.32M	$ 9.69M	$ 8.97M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 27.16M	$ 29.05M	$ 19.14M	$ 20.09M	$ 16.99M	$ 27.59M
Net Income From Continuing And Discontinued Operation	$ -24.57M	$ -27.47M	$ -8.15M	$ -19.36M	$ -16.17M	$ 22.98M
Normalized Income	$ -24.79M	$ -27.61M	$ -8.25M	$ -19.36M	$ -16.17M	$ -15.42M
Interest Expense	-	-	-	$ 0.00	$ 5.00K	$ 378.00K
EBIT	$ -27.16M	$ -29.05M	$ -19.14M	$ -20.09M	$ -16.16M	$ -27.32M
EBITDA	$ -27.12M	$ -29.00M	$ -19.08M	$ -20.03M	$ -15.94M	$ -26.95M

Currency in USD

Caladrius Biosciences Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing